Marketplace eNewsletter Bi-Monthly | Having trouble viewing this e-mail? Click here.
Pharmaceutical Technology/BioPharm Marketplace eNewsletter

Pharmaceutical Sciences, Manufacturing & Marketplace Report September 11, 2013
  From Cynthia Challener, PhD, Editor, Pharmaceutical Sciences, Manufacturing & Marketplace Report
In this issue, Novartis moves forward with a new Singapore biologics manufacturing facility that has a high degree of automation, and The Scripps Research Institute and Sigma-Aldrich form a partnership designed to reduce the transition time for moving new chemistry from the laboratory to commercialization. Plus, methods for predicting glass delamination for parenteral drugs, use of a heart-cutting, 2D UHPLC technique for rapid enantiomeric exccess determination, and a look at advances in foam granulation.		  
 

   
Stay current in the fast-paced world of biopharmaceutical and pharmaceutical development and manufacturing with a free subscription to the Pharmaceutical Sciences, Manufacturing & Marketplace Report.
 
Biological API Manufacturing
Image Placeholder
Maciej Frolow/Getty Images

Novartis Making Moves to Increase Biologics Manufacturing Capability

Novartis’ half-billion dollar investment in a new biologics production plant in Singapore represents a strategic commitment to its growing biologics portfolio. Click Here to Read More

Join our Biological API Manufacturing Linked-In Community
Chemical API Manufacturing
Image Placeholder
Alfred Pasieka/Getty Images
Sigma-Aldrich, The Scripps Research Institute Translating Research into Commercial Applications

A new partnership aims to eliminate months from the typical transition time required to move chemistry from the laboratory into commercial applications. Click Here to Read More
Join our Chemical API Manufacturing Linked-In Community
 
Parenterals
Image Placeholder
Maria Toutoudaki/Getty Images
Avoiding Glass Delamination with Early Product/Container Testing

Determining the potential for glass delamination before a product goes to market is the best way to ensure product safety and prevent expensive recalls. Click Here to Read More
Join our Parenterals Linked-In Community
 
Solid, Semisolid, and Specialty Dosage Forms
Image Placeholder
Ion-Bogdan Dumitrescu/Getty Images

Mechanical Control with Foam Granulation Well-Suited for Pharmaceutical Manufacturing

Foam granulation is much easier to control under mechanical dispersion conditions, which is where most industrial processes operate.Click Here to Read More

Join our Solid, Semisolid, and Specialty Dosage Forms Linked-In Community
 
Pharmaceutical Analysis
Image Placeholder
Adam Gault/Getty Images

Boehringer Ingelheim Pharmaceuticals Uses Two-Dimensional Ultra High-Pressure Liquid Chromatography in Process Development

2D-UHPLC enabled the simultaneous analysis of reaction conversion and enantiomeric excess in asymmetric hydrogenations. Click Here to Read More

Join our Pharmaceutical Analysis Linked-In Community
 
Other Recent Developments

Takeda Researchers Achieve Kilogram-scale GMP Production of a TORC1/2 Inhibitor
Installation of a quaternary chiral center with high enantioselectivity using memory of chirality enabled the six-step synthesis of the desired active compound.

UCLA Researchers Develop Nanocapsule for Targeted Delivery of Large-Molecule APIs
Reversible nanoencapsulation technology may make it possible to deliver high molecular weight drugs directly to target cancer cells, increasing efficacy and reducing side effects.

Making Cell-Imaging Systems More Accessible
Conventional cell-imaging systems that provide high quality data can be very expensive and complex to use. New systems from BioTek Instruments are designed to overcome these issues.

Porous Silica Gel Glidants Aid Direct Tablet Compression
Direct tablet compression is simpler than wet or dry granulation, but obtaining the right flow properties to ensure good compaction and uniform drug distribution can be a challenge. Porous silica gel, when used as a glidant, can address these issues.

Catalent Moves Forward with New Single-Use Biopharmaceutical Manufacturing Facility
Extensive adoption of single-use technologies and unidirectional flow reduces cross-contamination risk in the company's new biomanufacturing facility.

 
The Pharmaceutical Sciences, Manufacturing & Marketplace Report is a biweekly newsletter of Pharmaceutical Technology and BioPharm International, and an exclusive feature of the new Pharmaceutical Technology/BioPharm International Marketplace, an online community focused on products and services for drug development and manufacturing. The Pharmaceutical Sciences, Manufacturing & Marketplace Report provides insight in five main communities: solid, semisolid, and specialty dosage forms; parenterals; chemical API manufacturing; biological API manufacturing; and pharmaceutical analysis.  
 
Image Placeholder

Perspectives from Cynthia Challener, PhD, editor of the Pharmaceutical Sciences, Manufacturing & Marketplace Report and industry members
Image Placeholder Marketplace Report Blog
Image Placeholder

 
| Subscribe | Send Feedback | Advertise With Us | Visit pharmabiomarketplace.com |